Aldeyra Therapeutics

Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Aldeyra Therapeutics reports positive milestones and financial stability in Q4 2022

Aldeyra Therapeutics showcased positive performance in key milestones, financial stability, and progress in clinical studies, positioning the company for future growth.
Despite challenges in managing expenses and meeting enrollment deadlines, Aldeyra's strengths in its pipeline and financial position offer opportunities for success.
The upcoming year holds promise for Aldeyra with novel therapies addressing unmet medical needs and significant milestones expected in key trials.
Overall, Aldeyra's focus on advancing treatments for ocular and systemic conditions underscores its commitment to innovation and patient care.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call and webcast at 8:00 a.m. ET Thursday, January 7, 2021, to discuss top-line symptom, redness, and Schirmer's test results from the run-in cohort of the Phase 3 TRANQUILITY clinical trial in patients with dry eye disease. The main cohort of TRANQUILITY is expected to begin enrollment in February 2021, following completion of tear RASP analysis from the run-in cohort and confirmation

Aldeyra Therapeutics to Host Conference Call and Webcast to Discuss Top-Line Symptom, Redness, and Schirmer's Test Results from Run-in Cohort of Phase 3 TRANQUILITY Trial

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced confirmation of SARS-CoV-2 antiviral activity of ADX-1612, in addition to novel anti-inflammatory activity in SARS-CoV-2-infected primary human cells in preclinical studies. The results are derived from an international collaboration with the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) in Berlin, Germany, which plans additional studies with colleagues at the C

Aldeyra Therapeutics Announces Confirmation of Antiviral Activity of ADX-1612

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the initiation of Phase 2 clinical trials of ADX-629, a first-in-class orally administered reactive aldehyde species (RASP) inhibitor, for the treatment of COVID-19, atopic asthma, and psoriasis as part of a systematic strategy to assess activity across different types of immunological diseases. The Phase 2 clinical trials follow a successful Phase 1 clinical trial of ADX-629, which demonstrat

Aldeyra Therapeutics Announces Initiation of Phase 2 Clinical Trials of ADX-629, a First-in-Class Orally Administered RASP Inhibitor, for the Treatment of COVID-19, Atopic Asthma, and Psoriasis

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced enrollment of the first patient in the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease. The multi-center randomized, double-masked, parallel design, vehicle-controlled clin

Aldeyra Announces First Patient Enrolled in the Phase 3 TRANQUILITY Trial of Reproxalap for the Treatment of Dry Eye Disease

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the company's senior management will participate in the following virtual investor conferences: Jefferies Virtual London Healthcare Conference: Aldeyra President and CEO Todd C. Brady, M.D., Ph.D., is scheduled to participate in a fireside chat at 1:10 p.m. ET on Wednesday, November 18, 2020. The fireside chat will be broadcast live and archived for 90 days on the company's website at htt

Aldeyra Therapeutics to Participate in the Jefferies and A.G.P./Alliance Global Partners Virtual Investor Conferences

Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q3 2020 Results - Quick Version Earnings Call Transcript

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced financial results for the third quarter of 2020 and provided a corporate update. “Our novel RASP inhibitor reproxalap continues to progress toward New Drug Application (NDA) submissions for dry eye disease and allergic conjunct

Aldeyra Therapeutics Announces Third-Quarter 2020 Financial Results and Provides Corporate Update

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and CEO Todd C. Brady, M.D., Ph.D., will discuss Aldeyra's novel therapeutic approaches to treating anterior and posterior segment ocular disease at the Eyecelerator 2020 Virtual Conference on Friday, November 6, 2020. Dr. Brady's presentation is scheduled begin at 1:19 p.m. PT / 4:19 p.m. ET as part of Company Showcase III, “Advancing Trials in the Public Eye.” The presentation

Aldeyra to Participate in the American Academy of Ophthalmology Eyecelerator 2020 Virtual Conference on Friday, November 6

Shares of Aldeyra Therapeutics Inc (NASDAQ: ALDX), a company focusing on immune-mediated diseases, are primed for further upside, according to a Jefferies analyst.  The Aldeyra Analyst: Kelly Shi initiated coverage of Aldeyra shares with a Buy rating and $24 price target.

Aldeyra Has 'Catalayst-Rich' 12 Months Ahead, Jefferies Says In Bullish Initiation

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, will host a conference call at 8:00 a.m. ET on Thursday, November 5, 2020, to discuss financial results for the quarter ended September 30, 2020, and provide a corporate update. The dial-in numbers are (866) 211-4098 for domestic callers and (

Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third-Quarter 2020 Financial Results and Corporate Update

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that it will present new data from the Phase 2 allergen chamber clinical trial of reproxalap ophthalmic solution (0.25% and 0.5%) in allergic conjunctivitis. The data will be presented in a poster at the American Academy of Ophthalmology 2020 Virtual Annual Meeting (AAO 2020) from November 11 through November 15, 2020. In the randomized, double-masked, crossover, vehicle-controlled Phase 2 cli

Aldeyra to Present New Reproxalap Data from Phase 2 Clinical Trial in Allergic Conjunctivitis at American Academy of Ophthalmology 2020 Annual Meeting

An analyst is very bullish about the biotech stock.

Why Aldeyra Therapeutics Stock Soared Today

Is (ALDX) Outperforming Other Medical Stocks This Year?

Has Aldeyra Therapeutics (ALDX) Outpaced Other Medical Stocks This Year?

KemPharm

Minerva Neurosciences

Cassava Sciences Inc

4 Small Drug Stocks to Look Out For Amid Coronavirus Uncertainty

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc.

Aldeyra to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Aldeyra to Present at Cantor and H.C. Wainwright Virtual Investor Conferences

Aldeyra Receives Study May Proceed Letter from FDA to Initiate Clinical Trial of ADX-629 in COVID-19 Patients

Aldeyra to Participate in Citi’s 15th Annual BioPharma Virtual Conference

Aldeyra Therapeutics: A New Cure To A Serious 21st Century Problem

Apple

ChromaDex

Chevron

Home Depot

Intel

Johnson & Johnson

Merck

Nuveen Quality Municipal Income Fund

Verizon

Week 35 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

Aldeyra Therapeutics, Inc. (ALDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Aldeyra Therapeutics, Inc. (ALDX) Upgraded to Buy: Here's What You Should Know

Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q2 2020 Results - Earnings Call Transcript

Aldeyra (ALDX) reports narrower-than-expected loss in the second quarter of 2020.

Aldeyra's (ALDX) Q2 Earnings Beat Estimates, Pipeline in Focus

Aldeyra Therapeutics Announces Second-Quarter 2020 Financial Results and Provides Corporate Update

Aldeyra's (ALDX) pipeline progress will be in focus when it reports Q2 results later in the week.

Aldeyra (ALDX) to Report Q2 Earnings: What's in the Offing?

News for Aldeyra Therapeutics Stock (ALDX)